Coologics, a US-based clinical-stage medical device company, has successfully closed an oversubscribed seed funding round, raising over $3 million for its innovative vaginal infection treatment device, Vlisse.
The funding round, which doubled the company’s initial target of $1.5 million, was led by Prevail and Dream Ventures with participation from university alumni groups including Ohio State Early Investor Network and Illinois Ventures Illini Angels Program.
Vlisse represents a significant departure from traditional treatments for vaginal infections. The device utilizes a patented cooling mechanism to treat various vaginal infections, including VVC, BV, and mixed infections, without relying on antifungal drugs or antibiotics.
“We are beyond excited about the investor commitment to Coologics,” said Dr. Kim Langdon, Coologics CEO & Founder. “The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections. We are thrilled to welcome our new investors and leverage their expertise to accelerate our growth and deliver impactful solutions to female patients and their clinicians.”
The capital will fund the completion of Coologics’ ongoing clinical trial, FDA submission, and initial market release of Vlisse. The company’s focus on drug-free solutions addresses growing concerns about antibiotic resistance while offering women an alternative approach to managing common vaginal infections.
“Dr. Langdon’s vision and passion for this problem is what excited us the most about Coologics,” said Kerry Lawing, Prevail Ventures CEO. “This market is ripe for innovative solutions like Vlisse. I look forward to watching our experienced teams at Prevail and Dream strategically support Coologics efforts in bringing Vlisse to market.”
Founded by Dr. Langdon with Dr. Nicole Williams serving as Chief Medical Officer, Coologics aims to revolutionize women’s health with its approach of restoring the vaginal environment to a healthy state without chemicals. The successful funding round represents a significant milestone in bringing this technology to market.
